13TH ANNUAL

Accelerate discovery.Amplify returns.

REGISTER NOW!

October 7-8, 2014The Palace Hotel, San Francisco, CA

-1-

Why Attend BIO Investor Forum?INDEPENDENT HOST — One of the only independent investor conferences dedicated to helping early-stage biotech companies find sources of capital.

EFFICIENT PARTNERING — Ideal venue for investors and company executives to discuss financial and strategic business issues affecting investment in biotech companies and explore potential partnerships and business collaborations to fuel research and development for promising innovation.

GLOBAL SCOPE — Attracts healthcare venture capital and public market investors and research analysts as well as business development executives from leading global pharmaceutical and biotechnology companies.

COMPELLING VOICES — Offers ample networking opportunities, informative therapeutic and business workshops, and presentations from up-and-coming companies.

BIO Investor Forum by the Numbers71% of all U.S. therapeutic companies that have had an IPO in 2013 have attended the BIO Investor Forum at least once in the past four years.

Last year’s conference scheduled more than 900 meetings. Over 80% of all meeting requests were between biotech companies and investors.

The 2013 event welcomed 600 attendees and hosted nearly 120 late-stage private and emerging public companies that you won’t see at other investor conferences.

-2-

Advisory Committee

Srini Akkaraju, MD, PhDGeneral Partner, Sofinnova Ventures

Rajeev ShahPortfolio Manager, RA Capital Management

John ChambersManaging Director & Head of Healthcare Investment Banking, ROTH Capital Partners

Heather Preston, MDPartner and Managing Director, TPG Biotech

Asish K. Xavier, PhD Vice President, Venture Investments, J&J Development Corporation

Francesco De Rubertis Partner, Index Ventures

Jean-Francois FormelaPartner, Atlas Ventures

Gail MaderisPresident & CEO, BayBio

Douglas Fambrough, PhDCEO, Dicerna Pharmaceuticals

David H. Donabedian, PhDVice President, Head of Venture Investments & Early Stage Collabora-tions, Abbvie

Ramnarain “Joe” JaigobindHead of Global Equity Markets, Aegis Capital

Todd FoleyManaging Director, MPM Capital

Graeme Martin, PhDPresident & CEO, Takeda Ventures

Deepa PakianathanGeneral Partner, Delphi Ventures

Oleg NodelmanFounder and Managing Director, EcoR1 Capital Fund

-3-

Plenary Sessions

Opening Plenary Lunch: A High-Speed Option at the FDA: Lessons from Veterans of the Breakthrough Therapy Designation ProcessTuesday, October 7, 2014 | 12:00 p.m. - 1:25 p.m. | Twin Peaks North/SouthThe Breakthrough Therapy Designation (BTD) program instituted under the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 has produced its first set of accelerated approvals under this program, dramatically cutting time to market for some cancer, cystic fibrosis, and hepatitis C therapies. Our panelists will discuss the characteristics of successful applicants, what lessons they learned from their BTD program experience, and what advice they would give companies seeking to apply.

Moderator• Edward Dougherty, Principal, Dentons

Panelists• Cartier Esham, PhD, EVP Emerging Companies Section, BIO• William Lis, CEO, Portola Pharmaceuticals• Patrick J. McEnany, CEO, Catalyst Pharmaceutical Partners• Robert Ryan, MD, President and CEO, Scioderm

Plenary Lunch Session: BioCentury Presents: 22nd Annual “Back to School” ReportWednesday, October 8, 2014 | 12:30 p.m. - 1:25 p.m. | Twin Peaks North/SouthThe 22nd annual “Back to School” report from BioCentury brings a spotlight to drug pricing, and argues that biotech and pharma need to experiment with new pricing models based on value for money while they still have the chance. This session will focus on new pricing models; how to preserve incentives for the innovations that patients depend upon; and how to address potential resistance from boards and shareholders.

Closing Plenary: Up, Up, and Away: How Fragile is the Biotech Rally After Five Positive Years?Wednesday, October 8, 2014 | 3:30 p.m. - 4:25 p.m. | Twin Peaks North/South The past year has seen more biotech IPOs than the past five years combined and companies are going public earlier in their drug development than ever before. Public officials’ comments questioning whether there is a biotech “bubble” have created temporary market shocks before investor confidence returned. Are the innovative researchers and experienced investment community that brought the industry to its current peak communicating well enough to sustain this growth? What external threats deserve watching most closely?

Moderator• Todd Foley, Managing Director, MPM Capital

Panelists• David H. Donabedian, PhD, Vice President and Head of Venture Investments & Early Stage Collaborations, AbbVie• Rachel King, CEO (BIO, Chair), GlycoMimetics • Ellen Lubman, SVP Strategy and Innovation, Forest Laboratories • John Maraganore, PhD, CEO, Alnylam Pharmaceuticals• Michael A. Margolis, RPh, Managing Director, ROTH Capital Partners

-4-

Business Roundtables

JOBS Act, from Enactment to IPO: Surprises from the CEOs in the First GenerationTuesday, October 7, 2014 | 3:30 p.m. - 4:25 p.m. | Twin Peaks North/SouthThe JOBS Act has contributed to a dramatic acceleration in new biotech IPOs since its passage, with nearly a tripling in the rate of companies going public in the industry. By changing how entrepreneurs can access and communicate with investors earlier in the process, the JOBS Act has fundamentally shifted how CEOs of discovery-driven companies must spend their time dealing with internal versus external priorities. Panelists will discuss how investors’ expectations of biotech CEOs are changing and CEOs will describe new opportunities they have and surprises they encountered in taking their companies public in a post-JOBS Act environment, with implications for future entrepreneurs and policy experts.

Moderator• Cartier Esham, PhD, EVP Emerging Companies Section, BIO

Panelists• Paul J. Hastings, Chairman and CEO, OncoMed Pharmaceuticals • John Orwin, President and CEO, Relypsa • Effie Toshav, Partner, Fenwick & West LLP• Robert Ward, President and CEO, Radius Health

Blurred Lines: Explaining VCs’, CVCs’, and IBs’ Re-Thinking of Traditional Private-Only or Public-Only Investment StrategiesWednesday, October 8, 2014 | 2:00 p.m. - 2:55 p.m. | Twin Peaks North/SouthThe recent expansion and acceleration of the biotech stock market has seen a new willingness and in some cases eagerness to pursue crossover investing in firms pre- and post-IPO. Venture capitalists have become less dogmatic about funding stage and equity share when positive returns seem nearly guaranteed and investment banks are engaging in discussions with entrepreneurs earlier than ever. Relatedly, corporate venture capital executives’ missions have broadened to consider more diverse forms of collaboration than the path to full acquisition. This panel will discuss how temporary or permanent these shifts appear to be and the implications for biotech firms reaching out to the investment community.

Moderator• Michael J. O’Donnell, Partner, Morrison Foerster

Panelists• Jonathan Leff, Partner, Deerfield, andChairman,

Deerfield Institute • Graeme Martin, PhD, President and CEO,

Takeda Ventures • Oleg Nodelman, Founder and Managing Director,

EcoR1 Capital• Rajeev Shah, Portfolio Manager, RA Capital

(Speakers added daily. Please visit www.bio.org/investorforum for most up to date program and confirmed presenters).

Ebola UpdateA Conversation with Tekmira’s President and CEO, Mark Murray, PhD

Tuesday, October 7, 12:10 – 12:30 p.m.The biotechnology industry has been asked to accelerate its response in the face of this year’s record setting Ebola outbreak. We will discuss the tensions and the path forward with the CEO of Tekmira, a leading company developing an Ebola therapy.

-5-

Therapeutic Sessions

T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer TargetsTuesday, October 7, 2014 | 9:00 a.m. - 9:55 a.m. | Twin Peaks North/SouthNew approaches in cancer immunology are achieving promising early-stage results through novel techniques for arming the body’s own T cells to have greater impact on reducing tumors and preventing the spread of disease. CAR-T methods that extract, reengineer, and reintroduce a given patient’s T cells provide highly personalized therapy but may be difficult to scale up. The interleukin enhancement approach motivates existing T cells to be more potent and may be easier to deliver but have less pervasive effects. Early signs also suggest significant side-effect risks that will need to be understood and reduced for T-cell therapies to progress to commercialization. This panel will review priorities in the field for tailoring T-cell approaches to different cancer types and improving therapy efficiencies.

Moderator• Kristen Hege, MD, San Francisco Site Head, VP Translational Development, Hematology & Oncology, Celg0ene;

Assistant Professor, Department of Medicine, University of California, San Francisco

Panelists• David D. Chang, MD, PhD, EVP Research and Development, Chief Medical Officer, Kite Pharma• Jonathan Lewis, MD, PhD, CEO, ZIOPHARM Oncology• Richard Morgan, PhD, Vice President, Immunotherapy, bluebird bio• Timothy C. Rodell, MD, CEO and President, GlobeImmune

 

Gene Therapy Ascending? Today’s Advancements Over Past HurdlesWednesday, October 8, 2014 | 10:30 a.m. - 11:25 a.m. | Twin Peaks North/SouthSince the great excitements and disappointments of gene therapy’s first clinical era, the 1990s, researchers have revised traditional approaches and developed innovative new techniques, including CRISPR/cas-9, to edit genes with greater speed and precision than ever before.  Across a wide range of diseases, gene therapy is showing traction with fresh clinical results and attracting more than $600 million in venture capital in the past two years.  However, real challenges remain in delivery of therapies in sufficient concentrations to achieve lasting results without introducing harmful complications.  This panel will discuss the variety of strategies companies are employing to reduce risks and improve patient outcomes. 

Moderator• Eli A. Loots, PhD, Partner, Knobbe Martens

Panelists• Katrine Bosley, CEO, Editas Medicine• Thomas W. Chalberg, PhD, Founder and CEO, Avalanche Biotechnologies• Harry E. Gruber, MD, Chairman, CEO and President, Tocagen• Rachel Haurwitz, PhD, Founder, President and CEO, Caribou Biosciences

 

-6-

BIO is pleased to feature Ken Drazan and Nick Leschly as this year’s fireside chat speakers! Fireside chats feature candid discussions between biopharma senior executives and industry experts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2015.

Electroceuticals and Digital Drug Delivery: Neurological Stimulation and BeyondWednesday, October 8, 2014 | 9:00 a.m. - 9:55 a.m. | Twin Peaks North/SouthSome of the most experienced executives in biotechnology have begun asking themselves, “Can we foresee the day of diminishing returns from research in traditional molecular biology?” These researchers are investigating alternative modalities of providing therapy that would combine electronic sensing with drug delivery or even stimulating the body through electricity alone to produce a desired response. These “electroceutical,” or “bioelectronics,” approaches have produced exciting results in early clinical trials, particularly related to insulin control and pain management. These innovative approaches suggest opportunities to rejuvenate past drug candidates that might show more effectiveness through the introduction of implantable electronic sensors combined with injectors. Marrying the fast-cycle nature of the electronics industry with the deliberate approach of clinical trials involves risks in execution but great potential returns. A recent National Institutes of Health announcement to create a $248 million fund to support research in electroceuticals endorses the hope in this integrative approach.

Panelists• Cheryl R. Blanchard, PhD, CEO, microCHIPS• Christopher J. Czura, PhD, VP, Scientific Affairs, CFO, Elmezzi Graduate School of Molecular Medicine,

The Feinstein Institute for Medical Research• Juan-Pablo Mas, Partner, Action Potential Venture Capital• Martha J. Morrell, MD, Chief Medical Officer, NeuroPace

Fireside Chats

Ken Drazan, MD Johnson & Johnson Innovation, CaliforniaHead

Nick Leschly bluebird bioPresident & CEO

-7-

“ The BIO Investor Forum is the bellwether of life science investing and business creation. As such, it’s the must go to meeting on our calendar each year.”

— Graeme Martin, PhD, President & CEO, Takeda Ventures, Inc.

Participating Investors*

AbbVie Biotech VenturesAdvent Healthcare Ventures /

Synthesis CapitalAisling Capital LLCAlta PartnersAphelion CapitalApple Tree PartnersAquilo Capital ManagementAspire Capital PartnersAstellas Venture Management LLCATEL VenturesBay City CapitalBill & Melinda Gates FoundationBiomark CapitalBrace PharmaceuticalsBurrage CapitalBVF Partners, L.P.Cato BioVenturesClaremont Creek VenturesCleveland Clinic InnovationsCMEA CapitalConcord Venture CapitalDanken Ventures/Oresund CapitalDeerfield ManagementDefta PartnersDelphi VenturesEcoR1 CapitalEminent Venture Capital and TaiAn

Technologies, Inc.Enso VenturesFidelity BiosciencesFinTech Global Capital, LLCFoundation Venture Capital GroupGE Capital - Life SciencesGE Capital Healthcare Financial

ServicesGE Ventures

Healthco.Helix VenturesHercules Technology Growth CapitalInterWest PartnersInventis Investment Holdings (China) IPF PartnersJAFCO Life Science InvestmentJohnson & Johnson Development

CorporationJohnson & Johnson InnovationKearny Venture PartnersKPCBLatterell Venture PartnersLife Science AngelsLongitude Capital Management

CompanyLumira CapitalMBL Venture Capital Co., Ltd.Medimmune Ventures, Inc.Merlin NexusMilestone CapitalMizuho SecuritiesMP Healthcare Venture ManagementMPM CapitalMustang VCNew Jersey Health FoundationNew Leaf VenturesNoble Life SciencesNorwest Venture PartnersNovartis Venture FundNovo A/SNovo VenturesNSIP LLCOberland CapitalOpus Point PartnersOrbiMed

OrbiMed AdvisorsOxford Finance LLCPac-Link BioVenturesPalo Alto InvestorsPDL BioPharma, Inc.Phillip Private Equity Pte LtdPoliwoggPortola Capital Partners LLCPrecision BioventuresRA Capital ManagementSand Hill Angels 12, LLCSanofi-Genzyme BioVenturesSante VenturesSkyline VenturesSlater Technology FundSofinnova VenturesSR One LimitedSymphony Capital LLCSyzygy TherapeuticsTaiAn Technologies and Eminent

Venture Capital, Inc.Takeda Ventures, Inc.TavistockTech Coast AngelsTelegraph Hill PartnersThorner VenturesTVM CapitalVantagePoint Capital PartnersvenBioVenrock AssociatesVersant VenturesVivo CapitalWorld Bank Group/IFC Venture Capital

*As of 09/18/2014

Below is the preliminary list of 2014 participating investors for the BIO Investor Forum.

-8-

Presenting Companies

The following is the list of presenting companies for the 13th Annual BIO Investor Forum. Presenters will consist of Discovery Companies (under 25M raised to date in Seed or Series A financing rounds), established private companies (over 25M raised and in Series B and above) and emerging public companies.

DISCOVERY*Adjuvance TechnologyAeglea BioTherapeutics BionureAllinky BiopharmaAtterocorBell BiosystemsBioKierBioniz LLCBioNovion B.V.Biscayne PharmaceuticalsBNOAT OncologyCompuVaxCorbus PharmaceuticalsEnnaid TherapeuticsEternoGenETX Pharma, Inc.Felicitex TherapeuticsGrayBug LLCHumanetics Corp.InvivoSciences Inc.Makindus Inc.Meditope BiosciencesMentiNova, Inc.Molecular AssembliesOncoSynergyOrgaNext ResearchOrig3n Oricula TherapeuticsRecursion PharmaceuticalsRelburn-Metabolomics Inc.Rodin TherapeuticsSciodermStemsynergy TherapeuticsSulfagenixSyntrix BiosystemsTranslational SciencesTunitas Therapeutics

PRIVATE**AbGenomics InternationalActoGenix NVAdaptimmuneAlize PharmaAOBiomeApex TherapeuticsAridis PharmaceuticalsBEAT BiotherapeuticsBergBioClin TherapeuticsBlueprint MedicinesCebix, Inc.CerecorCoLucid PharmaceuticalsCortice BiosciencesCytomX TherapeuticsEnable Injections, LLCGenkyotex SAHenlius BiotechImmatics BiotechnologiesImmunGeneINHIBRxIsarna TherapeuticsJuventas TherapeuticsLoneStar Heart, Inc.Maverix BiomicsMAX BioPharmaMirna TherapeuticsMolecular TemplatesNexImmuneNuvOx PharmaOryzonOxyranePaxVaxPolynomaProtagonist TherapeuticsProvista DiagnosticsRuiYi Silver Creek Pharmaceuticals

Sutro BiopharmaTheravectysTolero PharmaceuticalsVascular PharmaceuticalsVivaBioCell

PUBLICApricus BioscienceAptose BiosciencesArgos TherapeuticsArno TherapeuticsAtossa GeneticsBenitecBioceptBio-Path HoldingsCareDxCatalyst Pharmaceutical

PartnersCelladon CorporationContraFect CorporationCortendo ABCritical Outcome

TechnologiesDicerna PharmaceuticalsGlobeImmuneGlycoMimeticsHeat BiologicsHorizon PharmaImmunovaccine Inc.Invion LimitedLpath Inc.Mast Therapeutics

Matinas BioPharmaMetaStatNeoStemNephroGenex Newron Pharmaceuticals

SpANovaBay PharmaceuticalsOcera Inc.OncoMed PharmaceuticalsOncoSec MedicalPalatin TechnologiesPfenexRadius HealthRelypsaRexahn PharmaceuticalsRXi PharmaceuticalsSophiris BioTekmira PharmaceuticalsTherapeuticsMDTrovagene, Inc.TxCell SA

PATIENT ADVOCACY GROUPS

Juvenile Diabetes Research Foundation

Michael J. Fox FoundationRare Cancer Research

FoundationThe Leukemia & Lymphoma

Society

SOLD OUT! * R&D companies in their Seed or Series A financing rounds with less than $25M raised to date. ** Companies that have raised >$25M, have raised Series B or later financings rounds, or are generating product revenues.

2013 Meeting Directionality

-9-

One-on-One PartneringTM Meetings

The BIO One-on-One Partnering™ System is the most efficient and economical way to develop new business relationships. This interactive environment allows you to increase your meeting productivity, discover new investment and licensing opportunities and expand your business partnerships worldwide. Using this online tool, you will be able to:

Pre-schedule 25-minute, private 1x1 meetings;

Search company and investor profiles, drug assets, products and services in the biotech and pharmaceutical industries;

Evaluate potential collaborations and funding opportunities with participating companies; and

Communicate directly with prospective investors and senior management.

For questions about the BIO One-on-One Partnering™ System, please contact biopartnering@bio.org.

More than 925 One-on-One meetings scheduled at BIF through BIO One-on-One Partnering™ in 2013

300+ companies150+ investors

3D130/170/20/35

Investor to Investor: 8%

Company to Investor: 72%

Company to Company:

20%

POWERED BY:

Attendee Profile

-10-

Audience Demographics

“ A fantastic way to meet with many potential investors and business partners. This way, I easily saved on 8-10 separate business trips.”

Over 40% of attendees were C-level Executives

3D130/170/20/35

Investors 34%

BD/Licensing 15%

Other 18%

Biotech Execs 33%

Investor Profile

3D130/170/20/35

Sell-Side Research: 8%

Venture Capitalist 60%

Portfolio Manager

9%

Buy-Side Research: 8%

Institutional Investor: 7%

Other 8%

-11-

Agenda*Tuesday

Marina Pacific Heights Presidio Sea Cliff Twin Peaks7-Oct-14

7:00 – 7:55am Networking Breakfast (Sunset Court)

8:00 - 8:25amBionure

BioClin Therapeutics Aridis Pharmaceuticals Sophiris BioAdjuvance Technology

8:30 – 8:55amMakindus Inc.

Cebix Inc. Heat Biologics Lpath Inc.Scioderm

9:00 – 9:25am

Recursion Pharmaceuticals

Genkyotex SA OncoSec MedicalCritical Outcome

Technologies

Therapeutic Workshop

T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing

Cancer Targets

Rare Cancer Research Foundation

9:30 – 9:55amAtterocor

Vascular Pharmaceuticals Biocept BenitecSulfagenix

10:00 – 10:25amAllinky Biopharma

Alize Pharma Bio-Path Holdings RXi PharmaceuticalsInvivoSciences

10:30 – 10:55amHumanetics Corp

Oxyrane Rexahn Pharmaceuticals Protagonist Therapeutics Fireside Chat

Ken Drazan, MD Head of Johnson & Johnson

Innovation, California

Translational Sciences

11:00 – 11:25amStemsynergy Therapeutics

PaxVax OncoMed Pharmaceuticals Blueprint MedicinesSyntrix Biosystems

11:30 – 11:55amOrgaNext Research

Theravectys Polynoma Maverix BiomicsFelicitex Therapeutics

12:00 – 1:25pm Welcome Remarks and Ebola Update: A Conversation with Tekmira’s President & CEO, Mark Murray, MD

(Box Lunches) Opening Plenary Lunch: A High-Speed Option at the FDA: Lessons from Veterans of the Breakthrough Therapy Designation Process

1:30 – 1:55pmBNOAT Oncology

LoneStar Heart Radius Health GlycoMimeticsMeditope Biosciences

2:00 – 2:25pmBioNovion B.V.

Silver Creek Pharmaceuticals

Horizon PharmaCatalyst Pharmaceutical

Partners Fireside Chat

Nick Leschly, CEO and President, bluebird bio

Biscayne Pharmaceuticals

2:30 – 2:55pmEnnaid Therapeutics

Ischemix Inc. Mast Therapeutics RelypsaBioniz LLC

3:00 – 3:25pmMolecular Assemblies

Juventas Therapeutics Ocera Inc. Cortendo ABEternogen

3:30 – 3:55pm Apex Therapeutics Oryzon NephroGenex ContraFect Corporation Business Roundtable

4:00 – 4:25pm NexImmune Sutro Biopharma Invion Limited Tekmira PharmaceuticalsJOBS Act, from Enactment to IPO: Surprises from the

CEOs in the First Generation

4:30 – 4:55pm Molecular Template Isarna Therapeutics NovaBay Pharmaceuticals AOBiome

5:00 – 7:00pm Reception (Garden Court)

Key:

Blue: Discovery Company Presentations

Purple: NIH SBIR/STTR Discovery Track Presentations

Green: Patient Advocacy Group Presentations

-12-

Please go to www.bio.org/investorforum for updates. *As of 09/18/2013

WednesdayMarina Pacific Heights Presidio Sea Cliff Twin Peaks North

8-Oct-14

7:30 – 8:25am Networking Breakfast (Sunset Court)

8:30 – 8:55amBell Biosystems

NuvOx Pharma Argos Therapeutics PfenexOncoSynergy

9:00 – 9:25am

Aeglea BioTherapeutics

Berg GlobeImmune Newron Pharmaceuticals Therapeutic Workshop

Electroceuticals and Digital Drug Delivery: Neurological

Stimulation and Beyond

Tunitas Therapeutics

9:30 – 9:55amCorbus Pharmaceuticals

immatics biotechnology Adaptimmune CoLucid PharmaceuticalsMichael J. Fox Foundation

10:00 – 10:25amMentiNova Inc.

Cortice Biosciences Dicerna Pharmaceuticals CerecorETX Pharma

10:30 – 10:55am

CompuVax

CytomX Therapeutics BEAT Biotherapeutics TherapeuticsMD Therapeutic Workshop

Gene Therapy Ascending? Today’s Advancements

Over Past Hurdles

Oricula Therapeutics

11:00 – 11:25amGrayBug LLC

Enable Injections LLC NeoStem Palatin TechnologiesBioKier

11:30 – 11:55am

Juvenile Diabetes Research Foundation

Mirna Therapeutics Celladon Corporation Apricus Bioscience

Relburn-Metabolomics

12:00 – 12:25pmLeukemia & Lymphoma

Society ImmunGene Matinas BioPharma TxCell SA

Rodin Therapeutics

12:30 – 1:25pmPlenary Lunch: BioCentury Presents: 22nd Annual “Back to School” Report

(Box Lunches)

1:30 – 1:55pm ActoGenix NV Tolero Pharmaceuticals Provista Diagnostics Immunovaccine Inc.

2:00 – 2:25pm INHIBRx Henlius Biotech MetaStat Aptose Biosciences Business Roundtable

Blurred Lines: Explaining VCs’, CVCs’, and IBs’

Re-Thinking of Traditional Private-Only or Public-Only

Investment Strategies

2:30 – 2:55pm VivaBioCell AbGenomics International CareDx Arno Therapeutics

3:00 – 3:25pm MAX BioPharma RuiYi Trovagene, Inc. Atossa Genetics

3:30 – 4:25pm Closing Plenary: Up, Up, and Away: How Fragile is the Biotech Rally After Five Positive Years?

4:30 – 5:30pm Closing Happy Hour (Sunset Court)

-13-

Registration

BIO offers a number of ways for conference attendees to save money on their registration fees. Discounted rates apply to the following:

Biotech companies that have raised less than $25 million in capital.

Presenting companies bringing three or more attendees.

Companies bringing more than two employees.

Corporations or other entities that use biotechnology or related technologies for research and development of products or information.

Academic institutions.

Qualified institutional and venture investors are eligible for complimentary registration.

Hotel/Venue InformationThe Palace Hotel 2 New Montgomery Street San Francisco, CA 94105Book your room today to also receive the discounted room rate for the Palace Hotel. Reservation requests are based on availability, space is limited.

Register today at bio.org/investorforum

3

3

3

3

3

SponsorsBank Sponsors

Industry SponsorBIO Double Helix Sponsors BIO Helix Sponsors

Conference Supporters

Media Partners

Contact us today for a tailored sponsorship package that will meet your business objectives. Contact George MacDougall at gmacdougall@bio.org or call 202-962-6689. For more information on BIO sponsorships, please visit www.bio.org/sponsor

Join the conversation:Learn more about Biotechnology at bio.orgEngage with the Biotech Community at BIOtech-NOW.orgFollow us on Twitter @bio1x1Become a fan on Facebook (facebook.com/IAmBiotech)

Local Co-Host

®

E x e c u t i v e & B o a r d S e a r c h

Strategic Advisors, Inc.Tiberend